Remarkable Stock Buzz: Advaxis, Inc. (NASDAQ:ADXS), Gold Standard Ventures Corp (AMEX:GSV) 2022/02/28 09:44:45 Stock Equity
Advaxis, Inc. (NASDAQ:ADXS) with the stream of 4.45% also noticed, India Gold Standard Ventures Corp (AMEX:GSV) encountered a rapid change of 4.07% in the last hour of trading session. Advaxis, … The post Remarkable Stock Buzz: Advaxis, Inc. (NASDAQ:ADXS), Gold Standard Ventures Corp (AMEX:GSV) appeared first on Stocks Equity .
Bright Stock Buzz: Advaxis, Inc. (NASDAQ:ADXS), BEST Inc. (NYSE:BEST) 2022/02/23 03:17:39 Stock Equity
Advaxis, Inc. (NASDAQ:ADXS) with the stream of 1.14% also noticed, India BEST Inc. (NYSE:BEST) encountered a rapid change of -18.64% in the last hour of Tuesdays trading session. Advaxis, Inc. The post Bright Stock Buzz: Advaxis, Inc. (NASDAQ:ADXS), BEST Inc. (NYSE:BEST) appeared first on Stocks Equity .
Advaxis GAAP EPS of -$0.14 beats by $0.03, revenue of $3.24M beats by $0.25M 2022/02/14 21:44:19 Seeking Alpha
Advaxis press release (ADXS): FY GAAP EPS of -$0.14 beats by $0.03.Revenue of $3.24M (+1196.0% Y/Y) beats by $0.25M.As of October 31, 2021, Advaxis had cash and cash…
Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update 2022/02/14 21:35:00 GlobeNewswire
MONMOUTH JUNCTION, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc . (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31, 2021 and provides a business update.
Advaxis prices $5M in convertible redeemable preferred stock offering 2022/01/28 13:30:00 Seeking Alpha
Advaxis (ADXS) entered into an agreement with certain institutional investors for the private placement of 1M shares of Series D convertible redeemable preferred stock.The shares to be
Outrageous stocks: Advaxis, Inc. (NASDAQ:ADXS -0.45%), Walmart Inc. (NYSE:WMT -0.43%) 2021/11/08 23:57:28 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Outrageous stocks: Advaxis, Inc. (NASDAQ:ADXS -0.45%), Walmart Inc. (NYSE:WMT -0.43%) appeared first on Stocks Equity .
Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting 2021/11/04 12:00:00 Intrado Digital Media
Company releases video message highlighting strategic rationale and benefits of proposed Biosight transaction for Advaxis stockholders
Advaxis (NASDAQ:ADXS) Stock Price Passes Above Two Hundred Day Moving Average of $0.47 2021/11/02 05:30:41 Dakota Financial News
Advaxis, Inc. (NASDAQ:ADXS) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.47 and traded as high as $0.51. Advaxis shares last traded at $0.51, with a volume of 5,980,256 shares. The firm has a market cap of $73.78 million, a P/E ratio of -2.67 
Advaxis Inc. (ADXS) Has Recovered 45.83% From Its Low: Is This The Beginning Of A Trend? 2021/10/29 15:00:00 Stocks Register
Advaxis Inc. (NASDAQ:ADXS) price on Thursday, October 28, fall -1.08% below its previous days close as a downside momentum from buyers pushed the stocks value to $0.48. A look at the stocks price movement, the close in the last trading session was $0.49, moving within a range at $0.469 and $0.50. The beta value (5-Year Advaxis Inc. (ADXS) Has Recovered 45.83% From Its Low: Is This The Beginning Of A Trend? Read More »
Now Is The Time To Build A Position In Advaxis Inc. (NASDAQ: ADXS) 2021/10/28 11:00:00 Marketing Sentinel
Advaxis Inc. (NASDAQ:ADXS)s traded shares stood at 7.43 million during the last session, with the companys beta value hitting 2.23. At the close of trading, the stocks price was $0.49, to imply a decrease of -0.95% or $0.0 in intraday trading. The ADXS shares 52-week high remains $1.57, putting it -220.41% down since that peak Now Is The Time To Build A Position In Advaxis Inc. (NASDAQ: ADXS) Read More »
ADVAXIS MAKING BOLD STEPS IN NEW CANCER STUDIES AND AGREEMENT WITH COLUMBIA UNIVERSITY 2021/04/20 17:06:19 Benzinga
Advaxis, Inc. (NASDAQ: ADXS ), CEO Ken Berlin presented at the Benzinga Biotech Small-Cap Conference on March 24, 2021. Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, is making new waves as it takes definitive steps to prove that the company is “no longer your grandfather’s Advaxis,” according to company CEO Ken Berlin. Among Advaxis’s new steps is an agreement with the Columbia University Irving Medical Center to fund a Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer. The company has also announced new data relating to developing a novel flow immunophenotyping assay to accurately evaluate total PD-1 expression as a pharmacodynamic marker during PD-1 blockade. It highlighted translational data demonstrating immune responses correlated to observed clinical benefit from Advaxis’s ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA®. The report was presented as a poster at this year’s American Association for Cancer Research (AACR) annual meeting.
Advaxis (NASDAQ:ADXS) Issues Quarterly Earnings Results 2021/03/19 05:14:42 Daily Political
Advaxis (NASDAQ:ADXS) posted its earnings results on Tuesday. The biotechnology company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.10, MarketWatch Earnings reports. Advaxis had a negative net margin of 13,144.62% and a negative return on equity of 81.49%. NASDAQ ADXS opened at $0.84 on Friday. The company […]
Advaxis Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis 2021/03/11 15:17:00 Stock Market Daily
Advaxis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Cancer Immunotherapy Market Analysis Focusing on Top Key Players - F. Hoffmann-La Roche AG, Advaxis Inc., Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, Immunomedics Inc 2021/03/05 15:43:34 OpenPR
The "Global Cancer Immunotherapy Market Analysis to 2027" is a specialized and in-depth study of the biotechnology industry with a particular focus on the global market trend analysis. The report aims to provide an overview of the cancer immunotherapy market
The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout 2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.